Total Payments
$59,838
2023 Payments
$2,298
Companies
3
Transactions
25
Payment Breakdown by Category
Other$50,000 (83.6%)
Research$9,405 (15.7%)
Food & Beverage$432.41 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Grant | $50,000 | 1 | 83.6% |
| Unspecified | $9,405 | 20 | 15.7% |
| Food and Beverage | $432.41 | 4 | 0.7% |
Payments by Type
General
$50,432
5 transactions
Research
$9,405
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $50,332 | 4 | $0 (2022) |
| Astellas Pharma Global Development | $9,405 | 20 | $0 (2023) |
| COLOPLAST CORP | $100.57 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,298 | 6 | Astellas Pharma Global Development ($2,298) |
| 2022 | $7,241 | 15 | Astellas Pharma Global Development ($7,107) |
| 2021 | $50,299 | 4 | BOSTON SCIENTIFIC CORPORATION ($50,198) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $739.28 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 04/24/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $509.30 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 04/23/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $294.64 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 03/10/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $176.25 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 02/21/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $283.97 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 01/19/2023 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $294.64 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 12/12/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $1,135.87 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 12/12/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $294.64 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 11/23/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $1,527.00 | Research |
| Study: Predicting mirabegron treatment response in patients with overactive bladder: A posthoc analysis of data from clinical trials • Category: Urology | ||||||
| 11/23/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $680.00 | Research |
| Study: Predicting mirabegron treatment response in patients with overactive bladder: A posthoc analysis of data from clinical trials • Category: Urology | ||||||
| 10/24/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | Cash or cash equivalent | $104.71 | Research |
| Study: Treatment Patterns in Men Prescribed Benign Prostatic Obstruction or Overactive Bladder Medications: A Canadian Retrospective Population-Based Study • Category: Urology | ||||||
| 08/02/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $31.06 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 07/22/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $2.04 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 07/08/2022 | Boston Scientific Corporation | AMS 700 CXR RTE Kit (Device) | Food and Beverage | In-kind items and services | $133.76 | General |
| Category: AMS 700 CXR RTE Kit_URO | ||||||
| 06/22/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $124.23 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 05/25/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $1,018.07 | Research |
| Study: Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data • Category: Urology | ||||||
| 05/25/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $155.29 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 03/11/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $1,419.84 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 03/11/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $50.96 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 02/17/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $104.71 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 01/20/2022 | Astellas Pharma Global Development | Myrbetriq (Drug) | — | In-kind items and services | $458.68 | Research |
| Study: Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study • Category: Urology | ||||||
| 09/21/2021 | BOSTON SCIENTIFIC CORPORATION | AMS 700 CXR RTE KIT (Device) | Food and Beverage | In-kind items and services | $87.45 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/09/2021 | BOSTON SCIENTIFIC CORPORATION | TACTRA (Device) | Food and Beverage | In-kind items and services | $110.63 | General |
| Category: PAIN MANAGEMENT | ||||||
| 05/18/2021 | BOSTON SCIENTIFIC CORPORATION | GENERAL ERECTILE DYSFUNCTION (Device) | Grant | Cash or cash equivalent | $50,000.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/22/2021 | COLOPLAST CORP | Titan (Device) | Food and Beverage | In-kind items and services | $100.57 | General |
| Category: Men's Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Treatment patterns in men prescribed benign prostatic obstruction or overactive bladder medications: a Canadian retrospective population-based study | Astellas Pharma Global Development | $3,941 | 10 |
| Predicting the response to mirabegron treatment in patients with overactive bladder: A post hoc analysis of clinical trial data | Astellas Pharma Global Development | $3,153 | 7 |
| Predicting mirabegron treatment response in patients with overactive bladder: A posthoc analysis of data from clinical trials | Astellas Pharma Global Development | $2,207 | 2 |
| Treatment Patterns in Men Prescribed Benign Prostatic Obstruction or Overactive Bladder Medications: A Canadian Retrospective Population-Based Study | Astellas Pharma Global Development | $104.71 | 1 |
About Dr. Rano Matta, MD
Dr. Rano Matta, MD is a Pediatric Urology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2020. The National Provider Identifier (NPI) number assigned to this provider is 1346868510.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rano Matta, MD has received a total of $59,838 in payments from pharmaceutical and medical device companies, with $2,298 received in 2023. These payments were reported across 25 transactions from 3 companies. The most common payment nature is "Grant" ($50,000).
Ad
Practice Information
- Specialty Pediatric Urology
- Location Salt Lake City, UT
- Active Since 07/14/2020
- Last Updated 11/20/2021
- Taxonomy Code 2088P0231X
- Entity Type Individual
- NPI Number 1346868510
Products in Payments
- GENERAL ERECTILE DYSFUNCTION (Device) $50,000
- Myrbetriq (Drug) $9,405
- AMS 700 CXR RTE Kit (Device) $133.76
- TACTRA (Device) $110.63
- Titan (Device) $100.57
- AMS 700 CXR RTE KIT (Device) $87.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Urology Doctors in Salt Lake City
Deborah Jacobson, Md, MD
Pediatric Urology — Payments: $2,639
Pediatric Urology $2,639
Brian Wiseman, Md, MD
Pediatric Urology — Payments: $1,406
Pediatric Urology $1,406
Dr. Robert Stephenson, M.d, M.D
Pediatric Urology — Payments: $1,375
Pediatric Urology $1,375
Dr. Michael Wallis, M.d, M.D
Pediatric Urology — Payments: $350.58
Pediatric Urology $350.58
Leah Stoehr, Aprn, APRN
Pediatric Urology
Pediatric Urology